November 9, 2008New England Journal of Medicine6,710 citationsOpen Access

Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein

PRPaul M. Ridker EDEleanor Danielson FFFrancisco Antônio Helfenstein Fonseca

Key Points

Cardiovascular events significantly decrease with statin treatment in those with elevated high-sensitivity C-reactive protein levels.
Statin therapy reduced high-sensitivity C-reactive protein alongside cholesterol, potentially improving heart health.
Assessment focuses on high-sensitivity C-reactive protein in relation to cardiovascular risk, indicating a need for targeted treatment strategies and further exploration of inflammation's role in heart health patterns within diverse populations. Highlights the importance of early intervention in inflammatory states to mitigate cardiovascular risks.

Abstract

Increased levels of the inflammatory biomarker high-sensitivity C-reactive protein predict cardiovascular events. Since statins lower levels of high-sensitivity C-reactive protein as well as cholesterol, we hypothesized that people with elevated high-sensitivity C-reactive protein levels but without hyperlipidemia might benefit from statin treatment.

Expert Takes9 quotes

1/9

“That is a larger reduction in the things that we care the most about — morbidity and mortality — than we've ever seen in a statin trial. And it occurred very quickly, in only 1.9 years of average duration of treatment.”

Steven Nissen, Chair of cardiovascular medicine, Cleveland ClinicCleveland Clinicauto_pipelineSupportiveView source

Ask AI

Helpful

Bookmark

View Full Paper